An interventional study of Luna Non-Contact Sleep Quality Monitor System in Sleep Disturbance, Sleep Disorder and Sleep Quality, sponsored by Indiana University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Indiana University · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 248 studies in Sleep Wake Disorders with a site in United States — 34 open to participants now, 40 under way, 8 of them phase 3. Sleep Wake Disorders · United States.
Among the 248 studies in Sleep Wake Disorders with a site in United States, this one is the 85th largest by planned enrollment of the 203 interventional ones that give a count, is one of 15 that started in 2026, is one of 123 with no phase, reaches primary completion later than 11 of the 39 other live ones, and was the 213th registered.
747 studies on the registry are indexed under Sleep Wake Disorders; 181 are open to participants now.
Browse Sleep Wake Disorders studies →34 of the 248 studies in Sleep Wake Disorders with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States
Ages 18+
Alkermes, Inc. · Sites in United States, Australia, Belgium and 10 more countries
Ages 18–70
Centessa Pharmaceuticals (UK) Limited · Sites in United States
Ages 18–70
VA Office of Research and Development · Sites in United States
Ages 60+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 114 Sleep Wake Disorders studies recruiting now, 40 (35%) set no upper age limit and 53 (46%) stop at 75 or younger; 22 take children under 18; 28 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
248 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 27 · Phase 3 30 · Phase 4 19
First in 1996; this study’s year is marked. 15 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 66 across 531 interventional studies indexed under Sleep Wake Disorders.
Median enrollment 70 across the 203 interventional studies, 110 across the 44 observational. Of the 189 that completed or were terminated, 67 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
56 of 248 have an industry lead sponsor. The 10 most frequent:
Indiana University is the lead sponsor of 991 studies on the registry; 202 are open to participants now.
Of its 150 completed or terminated interventional studies of FDA-regulated products, 118 (79%) have results posted.
Indiana University has 3 studies filed under Sleep Wake Disorders — fewer than ten, so there is no comparison to draw.
15 of the studies in Sleep Wake Disorders with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07502443Phase 3Alkermes, Inc.A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2 | 2027-05 |
| NCT07455383Phase 3Alkermes, Inc.A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 | 2027-05 |
| NCT07540897Phase 3Alkermes, Inc.A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304) | 2027-06 |
| NCT07598708Phase 3Centessa Pharmaceuticals (UK) LimitedA Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence | 2027-09-30 |
| NCT06843590Alkermes, Inc.A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia | 2026-11 |
Add all 15 to your calendar (.ics) → With an account.
Among the 248 studies in Sleep Wake Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate the effect of access to Luna device sleep system data on clinician documentation of sleep disorders and sleep treatments and participants' sleep quality. Participants who have sleep quality measured are long-term care (LTC) facility residents. The primary outcome of the trial is the following:
-Documentation of diagnosis or evidence of treatment of sleep disorders in the electronic health record (EHR) in long-term care (LTC) facility residents after 4 weeks of sleep monitoring and 2 weeks of clinical teams' receipt of resident sleep data. We hypothesize that, when real-time System Sleep Data is shared with the clinical team, i.e., LTC staff and healthcare providers in the facility, sleep disturbances will be more readily detected, leading to timelier, better tailored treatment interventions for sleep disturbances, thereby improving sleep quality.
All participating residents will:
Additionally, interviews and surveys will be done with LTC staff and healthcare providers in order to seek feedback and reflections on system use and the sleep data clinician user interface.
Sleep disturbances often lead to reduced health and lower quality of life and place burden on staff at care facilities. Unfortunately, clinical providers and staff in LTC facilities are limited in their ability to identify and treat these conditions as current methods of sleep quality assessment are either inaccurate, time consuming, or inappropriate for use in routine clinical practice.
The Luna device is a non-contact monitoring system that provides LTC institutions with a practical and enterprise-scale solution to quantify longitudinal sleep quality of residents to inform treatment decisions. Luna gives care providers the information they need to identify sleep disturbances and assess efficacy of interventions.
This trial is a before-after comparison study conducted within LTC facilities in central Indiana. LTC facility resident participants undergo 4 weeks of sleep monitoring by the Luna device. Documentation and sleep metrics of residents by the clinical team during the first 2 weeks participants undergo monitoring (and the clinical team has no Luna data access) to the second 2 weeks participants undergo sleep monitoring (with data access).
The primary outcome is documentation of diagnosis or evidence of treatment of sleep disorders in participating LTC residents' medical records after 4 weeks of sleep monitoring if data from the Luna device shows evidence of sleep disorders or disturbance.
We hypothesize that, when real-time System Sleep Data is shared with the clinical team, i.e., LTC staff and healthcare providers in the facility, sleep disturbances will be more readily detected, leading to timelier, better tailored treatment interventions for sleep disturbances, thereby improving sleep quality.
We also want to learn about the clinical team's experience interacting with the Luna device's data and interface and so will interview them about their experience after residents they take care of have undergone 4 weeks of sleep monitoring.
Each LTC resident participant will undergo a baseline and final (4-week) assessment that will include measures of sleepiness (Epworth Sleepiness Scale) and attitudes toward technology, technology acceptance, usability and utility. Additionally, one-time qualitative interviews and surveys will be done with LTC staff and healthcare providers in order to seek feedback and reflections on system use and the sleep data user interface.
The criteria were revised on the registry on Nov 19, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For the main outcomes:
-Resident of long-term care (LTC) facility study site location for a minimum of 30 days.
For the interviews and surveys conducted with LTC staff and healthcare providers:
Exclusion Criteria
For the main outcomes:
-Currently on hospice
For the interviews and surveys conducted with LTC staff and healthcare providers:
-Did not provide direct care to one or more participating residents during the resident(s)' participation in the main outcomes of the study
Participating residents undergo 4 weeks of sleep monitoring by the Luna device.
Device: Luna Non-Contact Sleep Quality Monitor System
Residents of long-term care facilities will utilize a sleep monitoring device for the four-week period they are involved in the study.
Documentation of diagnosis or treatment of sleep disorders
Documentation of diagnosis or evidence of treatment of sleep disorders in the electronic health record (EHR) in long-term care (LTC) facility residents after 4 weeks of sleep monitoring and 2 weeks of clinical teams' receipt of resident sleep data
Time frame: 4-weeks
Change in Total Nocturnal Sleep Time (TNST) as measured by the Luna device in participating LTC facility residents after 4 weeks of sleep monitoring.
Change in total duration of sleep that occurs during nighttime hours, as measured in minutes by the Luna device in participating LTC facility residents, after 4 weeks of sleep monitoring.
Time frame: 4-weeks
Change in Sleep Efficiency (SE) as measured by the Luna device in participating LTC facility residents after 4 weeks of sleep monitoring.
Change in the percentage of time participants spend sleeping while in bed, as measured by the Luna device in participating LTC facility residents, after 4 weeks of sleep monitoring.
Time frame: 4-weeks
Change in Sleep Onset Latency (SOL) as measured by the Luna device in participating LTC facility residents after 4 weeks of sleep monitoring.
Change in duration of time for participants to transition from wakefulness to sleep, as measured in minutes by the Luna device in participating LTC facility residents, after 4 weeks of sleep monitoring.
Time frame: 4-weeks
Change in Wake After Sleep Onset (WASO) count/duration as measured by the Luna device in participating LTC facility residents after 4 weeks of sleep monitoring.
Change in amount of wakefulness occurring after sleep onset, as measured in quantity and minutes by the Luna device in participating LTC facility residents, after 4 weeks of sleep monitoring.
Time frame: 4-weeks
Change in Epworth Sleepiness Scale total score in LTC facility residents after 4 weeks of sleep monitoring
The Epworth Sleepiness Scale is a validated, self-report measure of sleepiness. It is an 8-item questionnaire that measures one's tendency to become sleepy using a scale from 0 (no chance of dozing) to 3 (high chance of dozing). The total score is based on a scale of 0 to 24, with a score of 24 indicating the potential need for medical attention.
Time frame: 4-weeks
LTC facility residents' experience participating in the study after 4 weeks of sleep monitoring
A series of qualitative questions about attitudes toward technology, technology acceptance, usability, and utility
Time frame: 4-weeks
Feedback and reflections from participating LTC facilities' clinical teams on the Luna sleep system's use and its user data interface
Qualitative feedback and reflections from participating LTC facilities' clinical teams on the Luna sleep system's use and its user data interface after residents they take care of have participated in 4 weeks of sleep monitoring and clinicians have received 2 weeks of resident sleep data
Time frame: 4-weeks
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Feb 2027, 4 months after the start.
Of 214 non-industry interventional studies with no phase under Sleep Wake Disorders, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 40. This study's planned 4 months is below that.
Counting every sponsor, half of 249 studies reached it within 19 months; a quarter within 6 and three quarters within 37.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: start Jul 2026 → Oct 2026, primary completion Dec 2026 → Feb 2027 and completion Dec 2026 → Feb 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.